Tweet
Looks like Novavax is going to delay applying for FDA approval until after September - https://www.bloomberg.com/news/artic...cine-clearance - and instead is applying for approval in other countries, including India. Probably a smart move because the US market is pretty well saturated and vaccinations have slowed. Other articles have mentioned they may be positioning themselves as a booster alternative. They've been part of a study in the UK that's been looking at boosters from companies other than the original shot maker.
Was hoping they'd get US approval sooner since they're more of a traditional vaccine. Would have been interesting to see what people who don't want to get a mRNA type or said the current ones came out too fast would have done if there was an alternative and it was released almost a year after the mRNA ones. IMO anyone who also refuses something like Novavax is probably going to refuse any vaccine. Also, the vaccine pill from Vaxart probably won't even be out of trials until 2022, so those waiting for the pill version may have to wait awhile.
Was hoping they'd get US approval sooner since they're more of a traditional vaccine. Would have been interesting to see what people who don't want to get a mRNA type or said the current ones came out too fast would have done if there was an alternative and it was released almost a year after the mRNA ones. IMO anyone who also refuses something like Novavax is probably going to refuse any vaccine. Also, the vaccine pill from Vaxart probably won't even be out of trials until 2022, so those waiting for the pill version may have to wait awhile.
Comment